Furthermore, we have shown that the therapeutic effect of pevonedistat was T-cell-dependent, since (1) depletion of CD8+ T cells and (2) genetic knockout of β2-microglobulin in A20 lymphoma cells fully reversed the anti-tumor effect. This evidence concerns the gene CD8A and lymphoma.